| Number | Percentage |
---|---|---|
Age group | ||
 < 40 | 75 | 4.0 |
 40–49 | 570 | 30.4 |
 50–59 | 540 | 28.8 |
 60+ | 687 | 36.7 |
Median age (IQR) | 54 (47–64) | |
Menopausal status | ||
 Pre-menopausal | 788 | 42.1 |
 Post-menopausal | 1084 | 57.9 |
pN | ||
 pN0 | 1103 | 58.9 |
 pN1 | 449 | 24.0 |
 pN2 | 131 | 7.0 |
 pN3 | 189 | 10.1 |
pT | ||
 pT1 | 1060 | 56.6 |
 pT2 | 612 | 32.7 |
 pT3/4 | 200 | 10.7 |
Tumor grade | ||
 G1 | 279 | 14.9 |
 G2 | 1232 | 65.8 |
 G3 | 209 | 11.2 |
 Unknown | 152 | 8.1 |
Vessel invasion | ||
 No | 1797 | 96.0 |
 Yes | 75 | 4.0 |
Local treatment | ||
 Mastectomy w/o RT | 355 | 19.0 |
 Mastectomy w RT | 245 | 13.1 |
 Quadrantectomy w/o RT | 36 | 1.9 |
 Quadrantectomy w RT | 1236 | 66.0 |
Adjuvant treatment | ||
 ET | 1481 | 79.1 |
 CT+ET | 391 | 20.9 |
Hormonal therapy | ||
 Pre-menopausal | ||
  TAM | 107 | 13.6 |
  TAM+LHRH | 556 | 70.5 |
  AI+LHRH | 58 | 7.4 |
  Other | 67 | 8.5 |
 Post-menopausal | ||
  TAM | 483 | 44.6 |
  AI | 463 | 42.7 |
  Other | 138 | 12.7 |
Receptor status | ||
 Incompletely expressed (ER < 50 or PgR < 50) | 841 | 44.9 |
 Highly expressed (ER ≥ 50 and PgR ≥ 50) | 1031 | 55.1 |
Ki-67 | ||
 < 20% | 1375 | 73.5 |
 ≥ 20% | 497 | 26.5 |
HER2 | ||
 Not expressed | 1727 | 92.3 |
 Intense and complete | 72 | 3.8 |
 Unknown | 73 | 3.9 |
ER mean (SD)/median (IQR) | 83 (17)/90 (80–95) | |
PgR mean(SD)/median (IQR) | 51 (37)/60 (10–90) | |
Ki-67 mean(SD)/median (IQR) | 15 (9)/14 (9–20) |